EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes

Serge Ferrari iD, Donald Betah, Robert G Feldman, Bente L Langdahl, Mary Oates, Jen Timoshanko, Zhenxun Wang iD, Ruban Dhaliwal

The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · 2861-2868

DOI: 10.1210/clinem/dgae862 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 24.01.2025. Verfasst von Serge Ferrari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Geneva University Hospital, Geneva 1211, Switzerland. Hauptthemen laut MEDLINE: Bone Density, Cancellous Bone, Diabetes Mellitus, Type 2, Antibodies, Monoclonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Trabecular bone score (TBS), a gray-level texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) scans, is decreased in patients with diabetes and is associated with increased fracture risk, independent of areal bone mineral density (aBMD), but potentially influenced by abdominal fat tissue.

Objective

Evaluate effect of romosozumab (210 mg monthly) for 12 months followed by alendronate (70 mg weekly) for 24 months vs alendronate alone (70 mg weekly) for 36 months on LS aBMD and TBS in women with type 2 diabetes (T2D) enrolled in the ARCH study.

Methods

This post hoc analysis included women from ARCH who had T2D at baseline and LS DXA scans at baseline and ≥1 postbaseline visit (romosozumab-to-alendronate, n = 165; alendronate-to-alendronate, n = 195). aBMD and TBS (determined by an updated tissue thickness–adjusted TBS algorithm [TBSTT]) were assessed on LS DXA scans at baseline and ≥1 postbaseline visit (months 12, 24, and 36).

Results

Romosozumab led to significantly greater gains in LS aBMD and TBSTT at month 12 vs alendronate, and the greater gains with romosozumab were maintained after transition to alendronate and persisted significantly at months 24 and 36 vs alendronate alone. TBSTT percentage changes weakly correlated to LS aBMD percentage changes from baseline to month 36 (romosozumab-to-alendronate, R2 = 0.1493; alendronate-to-alendronate, R2 = 0.0429).

Conclusion

In postmenopausal women with osteoporosis and T2D, 12 months of romosozumab followed by 24 months of alendronate vs alendronate alone significantly improved LS aBMD and TBSTT (independently of abdominal fat) and to a greater extent. Hence, romosozumab may improve bone strength in patients with T2D.

Trial registration

ClinicalTrials.gov—NCT01631214

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityCancellous BoneDiabetes Mellitus, Type 2Antibodies, MonoclonalBone Density Conservation AgentsOsteoporosis, PostmenopausalHumansFemaleMiddle AgedAgedAbsorptiometry, PhotonAlendronateLumbar VertebraeDrug Therapy, Combination

Stichwörter der Autor:innen

DXAanabolicbone mineral densityfracture riskosteoporosistype 2 diabetes (T2D)

Substanzen

romosozumabAntibodies, MonoclonalBone Density Conservation AgentsAlendronate

Autor:innen und Institutionen

  • Geneva University Hospital, Geneva 1211, Switzerland.
  • Amgen Inc., Thousand Oaks, CA 91320, USA.
  • MemorialCare Saddleback Medical Center, Laguna Hills, CA 92653, USA.
  • Aarhus University Hospital and Aarhus University, 8200 Aarhus, Denmark.
  • UCB, Slough SL1 3WE, UK.
  • The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Serge Ferrari, Zhenxun Wang

Förderung

  • Astellas Pharma Inc
  • Amgen

Zitieren

APA

Ferrari, S., Betah, D., Feldman, R. G., Langdahl, B. L., Oates, M., Timoshanko, J., Wang, Z., & Dhaliwal, R. (2025). Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(10), 2861-2868. https://doi.org/10.1210/clinem/dgae862

Vancouver

Ferrari S, Betah D, Feldman RG, Langdahl BL, Oates M, Timoshanko J, et al. Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):2861-2868. doi:10.1210/clinem/dgae862

BibTeX
@article{Ferrari2025,
  author = {Ferrari, Serge and Betah, Donald and Feldman, Robert G and Langdahl, Bente L and Oates, Mary and Timoshanko, Jen and Wang, Zhenxun and Dhaliwal, Ruban},
  title = {Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {10},
  pages = {2861--2868},
  doi = {10.1210/clinem/dgae862}
}
Kostenlos starten →